Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ATM095
MIFTS: 64

Autoimmune Disease

Categories: Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Autoimmune Disease

About this section

MalaCards integrated aliases for Autoimmune Disease:

Name: Autoimmune Disease 57 12 29
Autoimmune Diseases 55 43 73
Hypersensitivity Reaction Type Ii Disease 12 15

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant gene epistatic to other secondary genes conferring specificity to the autoimmune phenotype


Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 109100
Disease Ontology 12 DOID:417
ICD9CM 35 720
MedGen 42 C0004364
Sources

Summaries for Autoimmune Disease

About this section
MedlinePlus : 43 Your body's immune system protects you from disease and infection. But if you have an autoimmune disease, your immune system attacks healthy cells in your body by mistake. Autoimmune diseases can affect many parts of the body. No one is sure what causes autoimmune diseases. They do tend to run in families. Women - particularly African-American, Hispanic-American, and Native-American women - have a higher risk for some autoimmune diseases. There are more than 80 types of autoimmune diseases, and some have similar symptoms. This makes it hard for your health care provider to know if you really have one of these diseases, and if so, which one. Getting a diagnosis can be frustrating and stressful. Often, the first symptoms are fatigue, muscle aches and a low fever. The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling. The diseases may also have flare-ups, when they get worse, and remissions, when symptoms get better or disappear. Treatment depends on the disease, but in most cases one important goal is to reduce inflammation. Sometimes doctors prescribe corticosteroids or other drugs that reduce your immune response.

MalaCards based summary : Autoimmune Disease, also known as autoimmune diseases, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and autoimmune disease of endocrine system. An important gene associated with Autoimmune Disease is GAS5 (Growth Arrest Specific 5
Increased lncRNA Gas5 activity in immune cells could suppress GR-induced transcriptional activity and contribute to the development of autoimmune disease.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ledipasvir and Sofosbuvir have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and t cells, and related phenotypes are autoimmune antibody positivity and hematopoietic system

Disease Ontology : 12 An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.

Wikipedia : 76 An autoimmune disease is a condition arising from an abnormal immune response to a normal body part.... more...

Description from OMIM: 109100
Sources

Related Diseases for Autoimmune Disease

About this section

Diseases related to Autoimmune Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 542)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 35.4 AIRE CTLA4 NLRP1 PTPN22
2 autoimmune disease of endocrine system 34.9 AIRE CTLA4 IFNG PTPN22
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 34.1 AIRE CTLA4 IFNG IL10 IL17A PTPN22
4 celiac disease 1 33.6 CD40LG CTLA4 IFNG IL10 PTPN22 TNF
5 graves' disease 33.6 AIRE CTLA4 IFNG PTPN22
6 mixed connective tissue disease 33.6 CD40LG IFNG IL10 TNF
7 lupus erythematosus 33.6 APOH CD40LG CTLA4 IL10 NLRP1 PTPN22
8 alopecia areata 33.5 AIRE CTLA4 IFNG PTPN22 TNF
9 autoimmune hepatitis 33.5 AIRE CD40LG CTLA4
10 multiple sclerosis 33.5 CTLA4 IFNG IL10 IL17A TNF TNFSF13B
11 myasthenia gravis 33.4 AIRE CTLA4 IFNG IL10 TNF TNFSF13B
12 hashimoto thyroiditis 33.4 AIRE CTLA4 IFNG PTPN22
13 vogt-koyanagi-harada disease 33.3 IL10 IL17A NLRP1 PTPN22
14 autoimmune myocarditis 33.3 IFNG TNF
15 rheumatoid arthritis 33.3 CD40LG CTLA4 IFNG IL10 IL17A NLRP1
16 psoriasis 33.2 IFNG IL10 IL17A PTPN22 TNF
17 systemic lupus erythematosus 33.2 APOH CD40LG CTLA4 IFNG IL10 IL17A
18 wegener granulomatosis 33.1 CTLA4 IFNG IL10 PTPN22 TNF
19 immunoglobulin a deficiency 1 33.0 CD40LG IL10
20 chronic active epstein-barr virus infection 32.9 CTLA4 IFNG IL10
21 autoimmune retinopathy 32.9 AIRE ENO1
22 reactive arthritis 32.9 IFNG IL10 TNF
23 melioidosis 32.9 IFNG IL10 TNF
24 immune deficiency disease 32.8 CD40LG IFNG IL10 TNF
25 diabetes mellitus, insulin-dependent 32.8 AIRE CTLA4 IFNG IL10 PTPN22
26 microscopic polyangiitis 32.7 IL10 TNF
27 interstitial lung disease 32.6 IFNG IL10 TNF
28 behcet syndrome 32.5 APOH CD40LG CTLA4 ENO1 IFNG IL10
29 immune system disease 32.5 APOH CD40LG CTLA4 IFNG IL10 IL17A
30 arthritis 32.1 IFNG IL10 IL17A NLRP1 PTPN22 TNF
31 hematopoietic stem cell transplantation 32.0 CTLA4 IFNG IL10 TNF
32 vasculitis 31.8 APOH CD40LG TNF TNFSF13B
33 uveitis 31.7 CTLA4 IFNG IL10 IL17A TNF
34 miller fisher syndrome 31.5 CD40LG TNF
35 colitis 31.5 IFNG IL10 IL17A TNF
36 connective tissue disease 31.4 APOH CD40LG IFNG IL10 TNF TNFSF13B
37 brucellosis 31.3 CD40LG IFNG IL10 TNF
38 chlamydia 31.3 CD40LG IFNG IL10 TNF
39 polyradiculoneuropathy 31.3 IFNG IL10 IL17A
40 candidiasis 31.3 AIRE IFNG IL10 IL17A
41 rubella 31.2 CD40LG IL10 TNF
42 graft-versus-host disease 31.2 IFNG IL10 TNF
43 common variable immunodeficiency 31.2 CD40LG CTLA4 IFNG IL10 TNF TNFSF13B
44 purpura 31.2 APOH CD40LG TNF
45 intermediate uveitis 31.2 IFNG IL10 TNF
46 spondylitis 31.2 CD40LG IL17A TNF
47 chronic graft versus host disease 31.2 IFNG IL10 TNFSF13B
48 cytomegalovirus infection 31.2 IFNG IL10 TNF
49 q fever 31.1 CD40LG IFNG IL10 TNF
50 schistosomiasis 31.1 CD40LG IFNG IL10 TNF

Graphical network of the top 20 diseases related to Autoimmune Disease:



Diseases related to Autoimmune Disease
Sources

Symptoms & Phenotypes for Autoimmune Disease

About this section

Symptoms via clinical synopsis from OMIM:

57
Immunology:
autoimmune disease

Lab:
high titer autoantibody


Clinical features from OMIM:

109100

Human phenotypes related to Autoimmune Disease:

32
# Description HPO Frequency HPO Source Accession
1 autoimmune antibody positivity 32 HP:0030057

MGI Mouse Phenotypes related to Autoimmune Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 SIAE IL10 STAT3 AIRE IL17A CD40LG
2 homeostasis/metabolism MP:0005376 10.03 PTPN22 IFNG IL10 AIRE APOH IL17A
3 endocrine/exocrine gland MP:0005379 10.02 PTPN22 IFNG IL10 AIRE IL17A CD40LG
4 digestive/alimentary MP:0005381 10.01 PTPN22 IFNG IL10 AIRE IL17A CTLA4
5 immune system MP:0005387 9.97 IFNG SIAE IL10 AIRE IL17A CD40LG
6 liver/biliary system MP:0005370 9.5 PTPN22 IFNG IL10 AIRE CTLA4 TNF
7 respiratory system MP:0005388 9.28 PTPN22 IFNG IL10 AIRE IL17A ITCH
Sources

Drugs & Therapeutics for Autoimmune Disease

About this section

Drugs for Autoimmune Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ledipasvir Approved Phase 4 1256388-51-8 67505836
2
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
3
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
4
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
5
Azithromycin Approved Phase 4,Phase 2,Phase 1 83905-01-5 55185 447043
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
7
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7782-49-2
8
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 159351-69-6 6442177
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
16
Enalapril Approved, Vet_approved Phase 4,Phase 2,Not Applicable 75847-73-3 5362032 40466924
17
Enalaprilat Approved Phase 4,Phase 2,Not Applicable 76420-72-9 6917719
18
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
19
Saxagliptin Approved Phase 4,Phase 3,Phase 2 361442-04-8 11243969
20
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
21
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
22
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
23
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114798-26-4 3961
24
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
25
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
26
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 133107-64-9
27
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
28
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
29
Glyburide Approved Phase 4,Phase 2,Phase 3,Not Applicable 10238-21-8 3488
30
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
31
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 446-86-6 2265
32
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Not Applicable 504-24-5 1727
33
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 189261-10-7
34
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
35
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
36
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147245-92-9 3081884
37
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
38
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
39
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118-42-3 3652
40
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
41
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 599-79-1 5353980 5359476
42
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
43
Diazoxide Approved Phase 4 364-98-7 3019
44
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
45
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
46
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 15307-86-5 3033
47
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2 202409-33-4 123619
48
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 332348-12-6 10237
49
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 16590-41-3 5360515
50
Allopurinol Approved Phase 4,Not Applicable 315-30-0 2094

Interventional clinical trials:

(show top 50) (show all 8327)
# Name Status NCT ID Phase Drugs
1 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
2 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
5 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
6 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
7 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
8 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
9 Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial Unknown status NCT01679561 Phase 4 intralipid
10 Selenium Supplementation in Youths With Autoimmune Thyroiditis Unknown status NCT02644707 Phase 4
11 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
12 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
13 The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes Unknown status NCT02307695 Phase 4 Saxagliptin;Insulin
14 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
15 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
16 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4 Commercial Hylenex® recombinant (hyaluronidase human injection);Precommercial Hylenex recombinant (hyaluronidase human injection);Insulin lispro;Insulin aspart;Insulin glulisine
17 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
18 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
19 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
20 Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
21 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
22 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
23 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
24 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
25 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
26 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Unknown status NCT00128895 Phase 4 azathioprine
27 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Unknown status NCT02849782 Phase 4 Fampridine
28 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
29 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
30 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
31 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
32 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
33 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
34 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
35 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
36 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
37 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
38 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
39 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
40 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
41 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
42 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
43 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
44 The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment Unknown status NCT02837978 Phase 4 Tacrolimus;MTX
45 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
46 Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
47 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
48 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
49 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
50 Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine Unknown status NCT01980836 Phase 4

Search NIH Clinical Center for Autoimmune Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Autoimmune Disease

About this section

Genetic tests related to Autoimmune Disease:

# Genetic test Affiliating Genes
1 Autoimmune Disease 29
Sources

Anatomical Context for Autoimmune Disease

About this section

MalaCards organs/tissues related to Autoimmune Disease:

41
Testes, Bone, T Cells, Thyroid, Eye, Brain, Pancreas
Sources

Publications for Autoimmune Disease

About this section

Articles related to Autoimmune Disease:

(show top 50) (show all 1599)
# Title Authors Year
1
Association between interleukin 37 (rs3811047) polymorphism and multiple autoimmune diseases in a Chinese population: A PRISMA-compliant meta-analysis. ( 29642198 )
2018
2
Anti-microbial Antibodies, Host Immunity, and Autoimmune Disease. ( 29876352 )
2018
3
Regulatory T cells in autoimmune disease. ( 29925983 )
2018
4
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. ( 29801110 )
2018
5
Myasthenia gravis: the unmet needs of a paradigmatic autoimmune disease. ( 29943694 )
2018
6
A Cross-Sectional Study of the Association between Autoantibodies and Qualitative Ultrasound Index of Bone in an Elderly Sample without Clinical Autoimmune Disease. ( 29854851 )
2018
7
Autoimmune-Disease-Prone NOD Mice Help To Reveal a New Genetic Locus for Reducing Pulmonary Disease Caused by Mycoplasma pulmonis. ( 29263105 )
2018
8
TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and <i>In Silico</i> Search for Small Molecule Binders. ( 29967617 )
2018
9
Association of Stress-Related Disorders With Subsequent Autoimmune Disease. ( 29922828 )
2018
10
The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population-based retrospective cohort study. ( 29955877 )
2018
11
Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. ( 28755788 )
2018
12
Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges. ( 29343274 )
2018
13
Autoimmune disease associated IFIH1 single nucleotide polymorphism related with IL-18 serum levels in Chinese systemic lupus erythematosus patients. ( 29930297 )
2018
14
Autoimmune disease: Targeting glucose transport in psoriasis. ( 29844603 )
2018
15
IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation. ( 29422534 )
2018
16
Autoimmune disease: Aryl hydrocarbon receptor suppresses inflammation. ( 29950706 )
2018
17
Lupus-like autoimmune disease caused by a lack of Xkr8, a caspase-dependent phospholipid scramblase. ( 29440417 )
2018
18
Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease. ( 29560011 )
2018
19
Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. ( 29776017 )
2018
20
Autoimmune disease, familial clustering and thyroid carcinoma coexistent with autoimmune thyroiditis in children and adolescence: A cross-sectional study from the Czech Republic. ( 29936527 )
2018
21
Impact of Dietary Cholesterol on the Pathophysiology of Infectious and Autoimmune Disease. ( 29899295 )
2018
22
Molecular mimicry: An explanation for autoimmune diseases and infertility. ( 29935034 )
2018
23
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. ( 29290269 )
2018
24
Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease. ( 29378858 )
2018
25
Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. ( 29412344 )
2018
26
Systemic autoimmune diseases are associated with an increased risk of bipolar disorder: A nationwide population-based cohort study. ( 29049933 )
2018
27
Anorexia, coeliac and autoimmune disease. ( 29317440 )
2018
28
The influence of thyroid diseases, diabetes mellitus, primary hyperparathyroidism, vitamin B12 deficiency and other comorbid autoimmune diseases on treatment outcome in patients with rheumatoid arthritis: An exploratory cohort study. ( 29794789 )
2018
29
Engineered Sialylation of Pathogenic Antibodies InA Vivo Attenuates Autoimmune Disease. ( 29275858 )
2018
30
Epigenetic editing: How cutting-edge targeted epigenetic modification might provide novel avenues for autoimmune disease therapy. ( 29421443 )
2018
31
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. ( 29297009 )
2018
32
Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions. ( 29341431 )
2018
33
An autoimmune disease-associated risk variant in the<i>TNFAIP3</i>gene plays a protective role in brucellosis that is mediated by the NF-kappa B signaling pathway. ( 29343543 )
2018
34
Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases. ( 29194620 )
2018
35
Atherosclerosis as autoimmune disease. ( 29955576 )
2018
36
Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-like Autoimmune Disease. ( 29959280 )
2018
37
Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. ( 29855994 )
2018
38
Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in <i>Aicda<sup>-/-</sup></i> and <i>Ung<sup>-/-</sup></i> Mice. ( 29980612 )
2018
39
Combination Therapy with Glucan and Coenzyme Q<sub>10</sub> in Murine Experimental Autoimmune Disease and Cancer. ( 29848676 )
2018
40
Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. ( 29205866 )
2018
41
C-terminal truncation of IFN-I^ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease. ( 29925830 )
2018
42
Approaches and advances in the genetic causes of autoimmune disease and their implications. ( 29925982 )
2018
43
Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. ( 29273217 )
2018
44
The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review. ( 29915581 )
2018
45
Hypoxia-inducible factor-1I+ is a critical transcription factor for IL-10-producing B cells in autoimmune disease. ( 29343683 )
2018
46
Biomimetic Nanosponges for Treating Antibody-Mediated Autoimmune Diseases. ( 29357234 )
2018
47
Remission of aggressive autoimmune disease (dermatomyositis) with removal of infective jaw pathology and ozone therapy: review and case report. ( 29959639 )
2018
48
The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. ( 28689782 )
2017
49
Treatment with Rutin - A Therapeutic Strategy for Neutrophil-Mediated Inflammatory and Autoimmune Diseases: - Anti-inflammatory Effects of Rutin on Neutrophils. ( 28392963 )
2017
50
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. ( 28586827 )
2017
Sources

Variations for Autoimmune Disease

About this section

Copy number variations for Autoimmune Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21625 1 159859611 159867782 Copy number FCGR3B Autoimmune disease
2 21792 1 161592989 161601158 Copy number FCGR3B Autoimmune disease
3 21796 1 161592989 161601158 Deletion FCGR3B Autoimmune disease
4 208909 6 211050653 211252076 Copy number CYP21B Autoimmune disease
5 210508 6 30400000 36600000 Copy number CYP21A Autoimmune disease
6 210509 6 30400000 36600000 Copy number TNXA Autoimmune disease
7 211044 6 3197570 32111174 Copy number C4A Autoimmune disease
8 211046 6 3197570 32111174 Copy number C4B Autoimmune disease
Sources

Expression for Autoimmune Disease

About this section
Search GEO for disease gene expression data for Autoimmune Disease.
Sources

Pathways for Autoimmune Disease

About this section

Pathways related to Autoimmune Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.97 CD40LG CTLA4 IFNG IL10 IL17A ITCH
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.28 CD40LG IFNG IL10 IL17A STAT3 TNF
3
Allograft rejection 1 37
Show member pathways
 12.72 CD40LG CTLA4 IFNG IL10 IL17A TNF
4
Regulation of IFNA signaling 66
Show member pathways
 12.55 IFNG IL10 IL17A STAT3 TNF
5
Immune response IL-23 signaling pathway 22
Show member pathways
 12.5 IFNG IL10 IL17A STAT3 TNF
6
Th17 cell differentiation 37
Show member pathways
 12.3 IFNG IL10 IL17A STAT3 TNF
7
IL-17 Family Signaling Pathways 65
Show member pathways
 12.24 IFNG IL17A STAT3 TNF
8
T cell receptor signaling pathway 37
Show member pathways
 12.14 CD40LG CTLA4 IFNG IL10 IL17A TNF
9
Th1 Differentiation Pathway 65
Show member pathways
 12.08 IFNG IL10 IL17A STAT3 TNF
10
Toxoplasmosis 37
Show member pathways
 12.04 CD40LG IFNG IL10 STAT3 TNF
11
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.99 IFNG IL10 IL17A STAT3 TNFSF13B
12
NF-kappaB Signaling 4
11.88 CD40LG CTLA4 IFNG IL10 IL17A ITCH
13
Interleukin-4 and 13 signaling 66
11.87 IL10 IL17A STAT3 TNF
14
HIF-1 signaling pathway 37
11.82 ENO1 IFNG STAT3
15
Amoebiasis 37
11.8 IFNG IL10 TNF
16
NF-kappa B signaling pathway 37
11.79 CD40LG TNF TNFSF13B
17
Dendritic Cells Developmental Lineage Pathway 65
11.67 IFNG IL10 TNF
18
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.66 CD40LG TNF TNFSF13B
19
Innate Lymphoid Cell Differentiation Pathways 65
11.66 IFNG IL10 IL17A TNF
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.58 CD40LG IFNG TNF
21
TGF-beta Receptor Signaling (WikiPathways) 1
11.54 IFNG STAT3 TNF
22